Skip to content 
The pitch is compelling: start Botox now, in your twenties, before wrinkles even form. Prevent lines from ever appearing. Your future self will thank you.
It sounds logical. And it has made “preventative Botox” one of the fastest-growing segments of aesthetic medicine. But when you examine what the research actually shows, a different picture emerges.
The science supports using Botox to prevent dynamic wrinkles from becoming permanent static lines. That’s real. What it doesn’t support is injecting faces that show no signs of wrinkles at all, which is what much of the “preventative Botox in your 20s” marketing implies.
Let’s look at what the evidence actually says.
The most-cited evidence for preventative Botox comes from a 2006 study published in the Archives of Facial Plastic Surgery. Researchers followed identical twins over 13 years, with one receiving regular Botox and the other receiving minimal treatment.
The results were dramatic. The regularly treated twin had significantly fewer imprinted lines in the forehead and around the eyes compared to her sister.
This study gets cited constantly to justify starting Botox as early as possible. But here’s what the marketing leaves out:
The twins started treatment at age 25. By the study’s conclusion, they were 38. A follow-up published in 2015 tracked them to age 44.
The treated twin had dynamic wrinkles when she started. She wasn’t injecting a perfectly smooth face. She was treating visible expression lines before they became etched in permanently.
The study compared regular treatment to almost no treatment. The minimally treated twin received Botox only twice over 13 years. This doesn’t tell us whether someone who starts at 35 will look worse at 48 than someone who starts at 25.
Untreated areas aged identically. The nasolabial folds (which weren’t treated) showed comparable aging in both twins. Botox prevented wrinkles specifically where it was injected, not general facial aging.
The twin study supports treating visible dynamic wrinkles before they become permanent. It doesn’t support injecting faces that don’t yet show any lines.
Understanding when different types of wrinkles develop helps clarify when treatment makes sense.
Dynamic wrinkles appear when you make facial expressions: smile lines, forehead creases when you raise your eyebrows, crow’s feet when you squint. In young skin, these disappear completely when your face relaxes.
Static wrinkles are lines that remain visible even when your face is at rest. They develop over time as dynamic wrinkles get “etched in” from repeated folding of skin that’s losing collagen and elasticity.
Here’s the typical timeline according to dermatological research:
Mid-20s: Collagen production begins declining (approximately 1% per year). Fine dynamic lines may become visible during expressions, particularly around the eyes.
Late 20s to early 30s: Dynamic wrinkles become more noticeable. For some people with fair skin or significant sun exposure, these lines may start to linger slightly after expressions.
30s: Dynamic wrinkles begin transitioning to static wrinkles in many people. Lines that once disappeared when you relaxed your face now remain faintly visible.
40s: Static wrinkles become established. Expression lines are visible at rest. This is when many wrinkles become truly “permanent” without intervention.
The key insight: in your early to mid-20s, most expression lines still disappear completely when you stop making the expression. There’s nothing to “prevent” yet because the etching process hasn’t begun.
Botox works by temporarily relaxing muscles, reducing the repetitive folding that eventually creates permanent creases. The prevention logic is straightforward: if you reduce the folding before lines become etched in, you can delay or minimize static wrinkle formation.
A 2022 evidence-based review in the Journal of Cosmetic Dermatology examined Botox use in young adults (under 41). The researchers found that “wrinkle prevention” was the most common reason younger patients sought treatment.
The clinical evidence supported the approach, with younger patients achieving excellent results with lower doses. The study recommended “an individualized approach with lower doses for younger adults.”
But notice what this actually means: treating patients who have dynamic wrinkles that are at risk of becoming static. The study examined patients who already had visible concerns.
The legitimate “preventative” window is when you start noticing that:
For most people, this happens in their late 20s to early 30s. Not at 22 with a perfectly smooth forehead.
The global botulinum toxin market is projected to reach nearly $6 billion by 2029. The aesthetic segment continues growing at double-digit rates annually.
Industry statistics reveal the reality of who’s actually getting Botox:
The average Botox patient is 43 years old. This is when static wrinkles have developed and treatment addresses an actual visible concern.
The 35 to 50 age group receives nearly half of all Botox procedures. These are people treating established wrinkles or preventing dynamic lines from becoming worse.
The 18 to 34 age group accounts for about 2.2 million treatments annually. This is the fastest-growing segment, but it still represents a minority of total procedures.
From a business perspective, the logic is clear: if you can convince people to start Botox 10 to 15 years earlier, you’ve potentially gained a customer for an additional decade of treatments. At $300 to $600 per session, three times per year, that’s tens of thousands of dollars over a lifetime.
This isn’t to say the aesthetic industry is malicious. But it is to say that marketing claims should be evaluated against clinical evidence, not accepted at face value.
The industry has adopted terms like “prejuvenation” and “baby Botox” to normalize treatment in younger demographics. These terms sound scientific but are primarily marketing constructs.
“Baby Botox” typically refers to lower doses (10 to 20 units versus 20 to 60 for established wrinkles). The smaller dose makes sense for someone with minimal lines. But it raises a question: if someone needs such a small dose because they have almost no wrinkles, do they need treatment at all?
The 2022 Journal of Cosmetic Dermatology study noted that younger, toxin-naive patients “are afraid to look frozen or unnatural.” Their primary motivation was prevention, not correction.
This creates a curious market: people paying for treatment specifically because they don’t have the problem treatment addresses. The appeal is entirely based on fear of future wrinkles.
To be clear: Botox works. It temporarily reduces muscle movement, which reduces skin folding, which can prevent lines from becoming etched in. This mechanism is well-established.
What the evidence supports:
Starting treatment when dynamic wrinkles are becoming prominent and beginning to linger. For most people, this is late 20s to early 30s.
Lower doses for younger patients. Less muscle activity needs less product to achieve results.
An individualized assessment. Some people develop dynamic wrinkles earlier due to genetics, sun exposure, or facial anatomy. Others don’t see significant lines until their 40s.
Regular maintenance produces cumulative benefits. The twin study and subsequent research suggest that consistent treatment over time produces better long-term outcomes than sporadic treatment.
What the evidence does not support:
Treating faces with no visible dynamic wrinkles. There’s no evidence that injecting a perfectly smooth 22-year-old face provides any benefit over waiting until dynamic wrinkles actually appear.
Assuming everyone needs to start at the same age. Skin aging varies dramatically based on genetics, lifestyle, and sun exposure.
The implication that starting later means worse outcomes. The twin study compared regular treatment to almost no treatment. It didn’t compare starting at 25 versus starting at 32.
Let’s do the math. Botox typically lasts 3 to 4 months, requiring roughly three treatments per year for maintenance.
If you start at 23 versus 33, and continue until age 60, here’s what you’re looking at:
Starting at 23: 37 years of treatment, roughly 111 sessions
Starting at 33: 27 years of treatment, roughly 81 sessions
Difference: 30 additional sessions
At $400 per session (a conservative estimate), that’s an additional $12,000 over a lifetime, not counting price increases or inflation.
The question is whether those 10 extra years of treatment, when you likely had few to no visible wrinkles, provided any benefit over starting when you actually needed it.
There’s no long-term study comparing outcomes of people who started at 23 versus 33. The evidence that exists shows benefits from treating dynamic wrinkles before they become static. But if you don’t have dynamic wrinkles worth treating until your 30s, starting earlier may just mean paying for treatment you don’t need.
Rather than starting Botox at an arbitrary young age, consider a more evidence-based approach:
Focus on proven prevention first. Sun protection is the single most effective anti-aging intervention. Sunscreen, hats, and avoiding excessive UV exposure prevent photoaging, which causes wrinkles independent of muscle movement. No injection can undo cumulative sun damage.
Watch for the transition from dynamic to static. Pay attention to whether your expression lines disappear completely when you relax your face. When they start lingering, that’s the legitimate window for preventative treatment.
Get an honest assessment. Ask a practitioner: “Do I actually have dynamic wrinkles that would benefit from treatment, or are you proposing treatment because I asked about it?” A good provider will tell you if you don’t need Botox yet.
Consider the tradeoffs. Some research suggests that long-term, repeated Botox use may cause muscle atrophy over time. Whether this matters clinically isn’t fully understood, but starting earlier means more years of treatment.
Remember what Botox doesn’t do. It addresses muscle-related wrinkles. It doesn’t prevent volume loss, skin laxity, sun damage, or changes in skin quality. It’s one tool, not a complete anti-aging solution.
“Preventative Botox” is a real concept supported by clinical evidence. Treating dynamic wrinkles before they become permanently etched can delay the development of static lines.
But the marketing has stretched this legitimate approach into something the evidence doesn’t support: injecting faces in their early 20s that show no visible wrinkles.
The twin study began at age 25, with twins who already had visible expression lines. The evidence supports treating visible dynamic wrinkles, not smooth skin. The average Botox patient is 43 because that’s when most people develop wrinkles worth treating.
If you’re in your early 20s with minimal expression lines, the most evidence-based “prevention” is sunscreen, not Botox. If you’re in your late 20s or 30s and noticing that lines are starting to linger, that’s when the preventative approach actually applies.
Starting treatment before you need it isn’t prevention. It’s paying for something that hasn’t become relevant yet. And for a $6 billion industry looking to expand its customer base, convincing young people they need treatment early is simply good business.
Considering whether Botox makes sense for you? At Kontour Medical Aesthetics, we believe in honest assessments. Our neuromodulator treatments start with a genuine evaluation of whether you’d benefit from treatment. Sometimes the answer is “not yet.” Contact us for a consultation that prioritizes your needs over treatment volume.
Related reading:
Stay informed with expert insights, treatment guides, and the latest developments in medical aesthetics from Nurse Practitioner Belita Savage.
